Clinical Trial Update: Efficacy and Safety of a 0.1% Tacrolimus Nasal Ointment as a Treatment for Epistaxis in Hemorrhagic Hereditary Telangiectasia (HHT) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating 0.1% tacrolimus nasal ointment for epistaxis in patients with hemorrhagic hereditary telangiectasia (HHT) completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemorrhagic Hereditary Telangiectasia

Drugs mentioned

• 0.1% tacrolimus nasal ointment (tacrolimus)

Snippet

Sponsor: Hospices Civils de Lyon | Conditions: Hemorrhagic Hereditary Telangiectasia (HHT) | Phase 2 | Status: COMPLETED | Results posted: 2020-07-01